During the project period, the LIACFLASH team successfully designed, developed, and validated the first medical linear accelerator (LINAC) capable of delivering both conventional and FLASH dose-rate electron radiotherapy, optimized for intraoperative use (IOeRT). The project reached TRL8 by May 2025, demonstrating full integration of key components including hardware, software, and AI-assisted treatment planning.
Key milestones included the optimization and functional validation of the LIACFLASH system (TRL7), followed by full-system qualification and pre-compliance testing for TRL8. The system is fully compatible with standard operating room (OR) environments and does not require dedicated shielding infrastructure. A dedicated imaging and planning unit—featuring proprietary AI-based algorithms—has been developed to enable fast, patient-specific intraoperative treatment planning.
Work on regulatory compliance progressed in parallel, with alignment to IEC 60601-2-1 safety standards, implementation of project-wide risk management strategies, and fulfillment of ethics-related deliverables.
The project’s dissemination and exploitation strategy included major events such as ESTRO 2025 and the launch of the FLASH MD! BE the FIRST scientific contest, which will award a LIACFLASH system on loan to a qualified EU clinical center. Promotional activities included website updates, digital campaigns, and printed materials.
Three new patent applications were submitted in 2025, covering the accelerator structure, the AI-based treatment planning module, and radiation safety innovations.
Initial conversations with potential strategic partners were initiated, and early co-investment interest has been registered, although formal agreements are still under evaluation.
A total of 14 scientific papers have been published during the project, including peer-reviewed journal articles and conference proceedings. Dissemination activities have also included participation in international events such as ESTRO and FRPT.
